231 related articles for article (PubMed ID: 30264681)
1. Development of Biodegradable Injectable In situ Forming Implants for Sustained Release of Lornoxicam.
Christian R; Thakkar V; Patel T; Gohel M; Baldaniya L; Shah P; Pandya T; Gandhi T
Curr Drug Deliv; 2019; 16(1):66-78. PubMed ID: 30264681
[TBL] [Abstract][Full Text] [Related]
2. Development of meloxicam in situ implant formulation by quality by design principle.
Ibrahim HM; Ahmed TA; Hussain MD; Rahman Z; Samy AM; Kaseem AA; Nutan MT
Drug Dev Ind Pharm; 2014 Jan; 40(1):66-73. PubMed ID: 23298324
[TBL] [Abstract][Full Text] [Related]
3. Polymeric and Non Polymeric Injectable In-situ Forming Implant Systems for Sustained Delivery of Lornoxicam: In vitro and In vivo Evaluation.
Yehia SA; Halim SAA; Aziz MY
Curr Drug Deliv; 2018; 15(8):1193-1203. PubMed ID: 29557743
[TBL] [Abstract][Full Text] [Related]
4. Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations.
Hamza Yel-S; Aburahma MH
Drug Dev Ind Pharm; 2010 Mar; 36(3):337-49. PubMed ID: 19722915
[TBL] [Abstract][Full Text] [Related]
5. Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation.
Ahmed TA; Alharby YA; El-Helw AR; Hosny KM; El-Say KM
Drug Des Devel Ther; 2016; 10():405-15. PubMed ID: 26855565
[TBL] [Abstract][Full Text] [Related]
6. Lappaconitine-loaded microspheres for parenteral sustained release: effects of formulation variables and in vitro characterization.
Xu H; Zhong H; Liu M; Xu C; Gao Y
Pharmazie; 2011 Sep; 66(9):654-61. PubMed ID: 22026119
[TBL] [Abstract][Full Text] [Related]
7. Niosomal gel of lornoxicam for topical delivery: in vitro assessment and pharmacodynamic activity.
Kumbhar D; Wavikar P; Vavia P
AAPS PharmSciTech; 2013 Sep; 14(3):1072-82. PubMed ID: 23818079
[TBL] [Abstract][Full Text] [Related]
8. Enhanced targeting efficiency of PLGA microspheres loaded with Lornoxicam for intra-articular administration.
Zhang Z; Bi X; Li H; Huang G
Drug Deliv; 2011; 18(7):536-44. PubMed ID: 21812757
[TBL] [Abstract][Full Text] [Related]
9. Injectable long acting chitosan/tripolyphosphate microspheres for the intra-articular delivery of lornoxicam: Optimization and in vivo evaluation.
Abd-Allah H; Kamel AO; Sammour OA
Carbohydr Polym; 2016 Sep; 149():263-73. PubMed ID: 27261750
[TBL] [Abstract][Full Text] [Related]
10. Comparative study on the in vitro performance of blister molded and conventional lornoxicam immediate release liquitablets: accelerated stability study and anti-inflammatory and ulcerogenic effects.
El-Setouhy DA; Gamiel AA; Badawi AA; Osman AS; Labib DA
Pharm Dev Technol; 2017 Mar; 22(2):256-265. PubMed ID: 27494155
[TBL] [Abstract][Full Text] [Related]
11. Asenapine maleate in situ forming biodegradable implant: an approach to enhance bioavailability.
Avachat AM; Kapure SS
Int J Pharm; 2014 Dec; 477(1-2):64-72. PubMed ID: 25305379
[TBL] [Abstract][Full Text] [Related]
12. Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats.
Shah H; Nair AB; Shah J; Bharadia P; Al-Dhubiab BE
Daru; 2019 Jun; 27(1):59-70. PubMed ID: 30701460
[TBL] [Abstract][Full Text] [Related]
13. Dissolution enhancement and formulation of rapid-release lornoxicam mini-tablets.
Tawfeek HM; Saleem IY; Roberts M
J Pharm Sci; 2014 Aug; 103(8):2470-83. PubMed ID: 24995853
[TBL] [Abstract][Full Text] [Related]
14. Novel sustained-release fast-disintegrating multi-unit compressed tablets of lornoxicam containing Eudragit RS coated chitosan-alginate beads.
Aburahma MH; Hamza Yel-S
Pharm Dev Technol; 2011 Aug; 16(4):316-30. PubMed ID: 20307250
[TBL] [Abstract][Full Text] [Related]
15. Intra-articular lornoxicam loaded PLGA microspheres: enhanced therapeutic efficiency and decreased systemic toxicity in the treatment of osteoarthritis.
Zhang Z; Huang G
Drug Deliv; 2012; 19(5):255-63. PubMed ID: 22775466
[TBL] [Abstract][Full Text] [Related]
16. Experimental optimization of Lornoxicam liposomes for sustained topical delivery.
Joseph J; B N VH; D RD
Eur J Pharm Sci; 2018 Jan; 112():38-51. PubMed ID: 29111151
[TBL] [Abstract][Full Text] [Related]
17. Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol.
Ahmed TA; Ibrahim HM; Ibrahim F; Samy AM; Kaseem A; Nutan MT; Hussain MD
J Pharm Sci; 2012 Oct; 101(10):3753-62. PubMed ID: 22753324
[TBL] [Abstract][Full Text] [Related]
18. Sonication-assisted drug encapsulation in layer-by-layer self-assembled gelatin-poly (styrenesulfonate) polyelectrolyte nanocapsules: process optimization.
Pandey AP; Singh SS; Patil GB; Patil PO; Bhavsar CJ; Deshmukh PK
Artif Cells Nanomed Biotechnol; 2015; 43(6):413-24. PubMed ID: 24684490
[TBL] [Abstract][Full Text] [Related]
19. Optimization and Characterization of Brimonidine Tartrate Nanoparticles-loaded In Situ Gel for the Treatment of Glaucoma.
Sharma PK; Chauhan MK
Curr Eye Res; 2021 Nov; 46(11):1703-1716. PubMed ID: 33844617
[No Abstract] [Full Text] [Related]
20. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
Desai KG; Mallery SR; Schwendeman SP
Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
